Avacta Group (AVCT)
AVCT Share PerformanceMore
|52 week high||98.00 26/05/17|
|52 week low||39.00 20/03/18|
|52 week change||-27.50 (-41.35%)|
|4 week volume||518,166 22/02/18|
Media for (AVCT)
Latest News« previous» nextMore
13/03/2018 - 12:30 StockMarketWire
Prof Alastair Smith, Chief Executive Officer, bought 35,800 shares in the company on the 13th March 2018 at a price of 41.9...
13/03/2018 - 12:02 RNS
RNS Number: 5787H Avacta Group PLC 13 March 2018 13 March 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director/PDMR Shareholding Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today purchased 35,800 ordinary shar...
07/03/2018 - 16:35 RNS
RNS Number: 0323H Avacta Group PLC 07 March 2018 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before the execution o...
08/02/2018 - 07:00 RNS
RNS Number: 2482E Avacta Group PLC 08 February 2018 8 February 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Capital Markets Day Strong Progress and Milestones Outlined to 2021 Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to provide a review of progress against the objectives set in...
02/02/2018 - 16:06 Interactive Investor
It takes companies years to develop new products or technology, but former AIM writer of the year Andrew Hore has fou...
22/01/2018 - 07:00 RNS
RNS Number: 4499C Avacta Group PLC 22 January 2018 22 January 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta and OncoSec to Collaborate on Innovative Gene Delivery of Therapeutic Affimers Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, and OncoSec Medical Incorporated ("OncoSec") ...
18/01/2018 - 11:26 RNS
RNS Number: 2759C Avacta Group PLC 18 January 2018 18 January 2018 Avacta Group plc ("Avacta", "the Group" or "the Company") Result of Annual General Meeting Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents announces that at the Annual General Meeting held earlier today, all resolutions were duly passed. The full t...
18/01/2018 - 07:31 StockMarketWire
Avacta expects revenue, operating losses and cash balances for the six months ending 31 Jan to be in line with market forec...
|Dividend yield||0 %|
Latest discussion posts More
“albeit technical and above me - though we do seem to have a growing number of same but as we all know converting same into revenue and substantial revenue is the only driver ...”▼
“agree re hopefully - but will still wait a tad longer at least our ceo is continuing to buy on open market - perhaps some other pdmrs could follow his example (m albin's as ...”▼
“Directors buying now. Hopefully this is the bottom.”▼
Codes & Symbols
|Symbols||AVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT|